Clinical Trial: Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer

U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT04822298) titled 'Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer' on March 26.

Brief Summary: This study aims to evaluate the safety and tolerability of AMG 160 and to evaluate the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D).

Study Type: Interventional

Condition: * Non-small Cell Lung Cancer

* NSCLC

Intervention: Drug: AMG 160

AMG 160 administered as an intravenous (IV) infusion

Recruitment Status: Not Yet Recruiting

Sponsor: Amgen

Information provided by (Responsible Party): Amgen

Published by HT Digital Content Services with permission from Health Daily Digest....